[A17-43] Tofacitinib (rheumatoid arthritis) - Addendum to Commission A17-18
Last updated 19.10.2017
Commission awarded on 04.09.2017 by the Federal Joint Committee (G-BA).
Muscles, bones and joints
Moderate to severe rheumatoid arthritis in adult patients with insufficient response to prior treatment
For patients ≤ 65 years with unfavourable prognosis pretreated once no hint of lesser benefit versus adalimumab. For 4 questions added benefit therefore not proven.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.